New hope for rare bleeding disorder: experimental drug tested in small study
NCT ID NCT04770935
First seen Nov 01, 2025 · Last updated May 20, 2026 · Updated 33 times
Summary
This early-stage study tested a single injection of a new drug called BIVV001 in 6 adults with type 2N or 3 von Willebrand disease, a rare bleeding disorder. The main goals were to see how the drug behaves in the body and whether it is safe. The study was completed, but results are not yet public.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VON WILLEBRAND'S DISEASE (VWD) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Hemophilia Center of Western Pennsylvania_Investigational Site Number :8400001
Pittsburgh, Pennsylvania, 15213, United States
-
Investigational Site Number :2500001
Lille, 59037, France
-
Investigational Site Number :2500002
Nantes, 44093, France
-
University of Iowa_Investigational Site Number :8400002
Iowa City, Iowa, 52242, United States
Conditions
Explore the condition pages connected to this study.